Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
This facility manufactures APIs & formulations of oncology and non-oncology products.
This facility manufactures APIs & formulations of oncology and non-oncology products.
A significant proportion of healthcare professionals still tend to favor branded drugs
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Highly effective preservation solutions ensuring the safety and protection of personal care products
The company plans to add 1700 beds by FY27 through the organic route
International Business is expected to register double-digit growth in constant currency terms
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Subscribe To Our Newsletter & Stay Updated